Stock Analysis
Edwards Lifesciences Corporation (EW) Stock Analysis
Edwards Lifesciences Corporation (EW) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Edwards Lifesciences Corporation (EW) currently has an AIQ Score of 46/100, indicating a neutral setup. Risk is the strongest factor at 77/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
EW at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $84.37 |
| AIQ Score | 46/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $52.25B |
| P/E Ratio | 33.61 |
| Forward P/E | — |
| EPS | $0.42 |
| Revenue TTM | $1.74B |
| Dividend Yield | 0.00% |
| Beta | 0.85 |
| Volume | 3.8M |
| 52-week range | $72.30-$96.29 |
| RSI 14 | 24.81 |
| 50-Day SMA | $89.23 |
| 200-Day SMA | $84.97 |
| Analyst Price Target | $100.00 |
| Next Earnings | Oct 29, 2026 |
EW
OverviewEW Stock Analysis Summary
Edwards Lifesciences Corporation (EW) currently has an AIQ Score of 46/100, indicating a neutral setup. Risk resilience is the strongest factor at 77/100. Momentum is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, EW has AIQ Score of 46/100 with Risk resilience base of 77/100 and fading Momentum at 23/100. Wait for component alignment before adding exposure.
Risk resilience (77/100) leads while Momentum (23/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.77% stock move · EW classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is EW Bullish or Bearish Right Now?
EW currently has a neutral overall setup. Risk Resilience is the strongest factor at 77/100, while Momentum is weakest at 23/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 69/100.
- - Risk Resilience is supportive at 77/100.
- - Analyst target implies +18.53% upside from the latest quote.
- - Value is the current constraint at 28/100.
- - Momentum is weak at 23/100.
- - Price is -0.71% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (36 vs 8).
Current Consensus
EW's Technical Analysis Consensus is currently Strong Sell, with 8 buy, 1 neutral, and 36 sell votes. EW's 14-day RSI is 24.81, which places the stock in an oversold momentum range. EW's beta is 0.85, indicating market sensitivity broadly in line with the market.
What Changed in EW?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the EW Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
EW Decision Framework
Public evidence layers, setup checks, and risk context for Edwards Lifesciences Corporation.
Edwards Lifesciences Corporation (EW) Stock Analysis
Edwards Lifesciences Corporation has an AIQ Score of 46/100 in a Neutral regime. Risk is strongest at 77/100. Beta is 0.85, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | EW is in a Neutral AIQ regime with score 46/100. |
| Signal Conflict | The primary conflict is that risk leads at 77/100 while momentum lags at 23/100. |
| Factor Evidence | Momentum 23/100 · Value 28/100 · Quality 69/100 · Risk 77/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 77/100.
Momentum is 23/100 and RSI (14) is 24.8.
EW is in a Neutral regime at 46/100.
Risk factor is 77/100 with beta 0.85 and annual volatility 25.38%.
Current conflict: risk leads at 77/100 while momentum lags at 23/100.
EW Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
EW Fundamentals
EW valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
EW Technical Analysis
EW technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
EW Stock Catalysts
Track EW earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
EW Dividend Analysis
EW dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
EW Financial Data
EW revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
EW Risk Analysis
EW volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
EW Stock News
EW stock news, market tone, recent headlines, and catalyst context.
EW vs Medical Devices Peers
Current peer cohort: EW · GEHC · GMED · HAYW · HOLX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| EW Current stock | 46/100 | 28/100 | 23/100 | 77/100 | 0.27 | 25.38% | Current |
| GEHC GE HealthCare | 49/100 | 65/100 | 21/100 | 60/100 | -0.43 | 35.02% | EW vs GEHC |
| GMED Globus Medical | 54/100 | 55/100 | 21/100 | 75/100 | 0.63 | 48.96% | EW vs GMED |
| HAYW Hayward Holdings | 55/100 | 64/100 | 25/100 | 74/100 | -0.5 | 33.10% | EW vs HAYW |
| HOLX Hologic | 54/100 | 37/100 | — | 81/100 | 1.18 | 16.42% | EW vs HOLX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching EW
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for EW
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
EW Stock FAQ
What is EW stock price today?
Edwards Lifesciences Corporation's current stock price is $84.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is EW bullish or bearish right now?
EW's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is EW's market cap?
EW's market cap is $52.25B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is EW's current P/E ratio?
EW's current P/E ratio is 33.61 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is EW's RSI?
EW's 14-day RSI is 24.81 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is EW above its 50-day and 200-day moving averages?
EW is -5.45% from its 50-day SMA and -0.71% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is EW's next earnings date?
EW's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does EW pay a dividend?
EW's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.